Alimera Sciences Inc., of Atlanta, finished 2015 at 167 percent above the previous year's revenue, thanks mainly to Iluvien (fluocinolone acetonide) for diabetic macular edema. The product sold $22.4 million globally, the firm said, in line with expectations set during the third quarter earnings call last year.